PCI Biotech - Småprat (PCIB)

[Kul1]

Nå folkens er tiden inne for å kjøpe tusenvis av aksjer i PCI Biotech - selskapet som er kjent for sin ærlige og gode kommunikasjon med aksjonærene.

Dette er øyeblikket hvor det skjer. Fra nå av kan det bare skje en av tre ting:

• Aksjen går opp

• Aksjen går sidelengs

• Aksjen går ned

Jeg gir ikke aksjeråd, men jeg gjør det.

[TheLion]

Da er jeg igjen på plass. Leste gjennom alt jeg kunne finne og hørte på div. podcast .
2025 blir spennende.

Lykketil.
PCIB AAV New Orleans .pdf (3,0 MB)

AI Superbot gir følgende sammendrag av AAV New Orleans :

Based on the presentation from PCI Biotech, the “value” lies primarily in improving the manufacturing productivity of AAV gene therapies to make them more accessible. Their technology, Photochemical Lysis (PCL), aims to selectively release viral vectors from producer cells.

Key value points:

• Increased Batch Yield: PCL has the potential to increase AAV batch yields, which is critical because current manufacturing processes are resource-demanding and inefficient.
• Reduced Host-Cell Impurities: The technology also reduces host-cell impurities, simplifying downstream processing.
• Cost Savings: Increased yields and reduced impurities can lead to significant cost savings in manufacturing.

Possible market value, as shown on slide 12, demonstrates the asset value potential. The y-axis represents estimated total market in (USD M). The x-axis represents the years.

The x-axis in AAV batch yield increase (%) represents Asset value in (USD M) and PCL asset value is exemplified for 2028.

• The market value will be from 500 million to 3000 USD M from the year 2023 to the year 2033.
• The graph represents how much the asset value in USD M and the AAV batch yield increase in percentages.

Overall, the presentation highlights PCL’s potential to improve AAV manufacturing, increase productivity, and lower costs, which translates to significant value in the gene therapy space.